Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family that inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Gatifloxacin is a fluoroquinolone antibiotic, with potent activity against Gram-negative and Gram-positive bacteria. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin for the treatment of respiratory tract infections. Allergan produces it in eye-drop formulation under the names Zymar and Zymaxid. In many countries, gatifloxacin is also available as tablets and in various aqueous solutions for intravenous therapy.
Catalog Number | A000459 |
CAS Number | 112811-59-3 |
Synonyms | 112811-59-3; Tequin; Zymar; Gatiflo; Gatifloxacine |
Molecular Formula | C19H22FN3O4 |
Purity | ≥95% |
Target | Topoisomerase |
Solubility | Limited solubility |
Storage | -20°C |
InChI | 1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26) |
InChIKey | XUBOMFCQGDBHNK-UHFFFAOYSA-N |
SMILES | CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F |
Reference | 1: Dawn A, Chandra H, Ade-Browne C, Yadav J, Kumari H. Multifaceted 2: Pienaar E, Sarathy J, Prideaux B, Dietzold J, Dartois V, Kirschner DE, 3: Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H. In 4: Xu Z, Zhang S, Song X, Qiang M, Lv Z. Design, synthesis and in vitro 5: Xu Z, Song XF, Hu YQ, Qiang M, Lv ZS. Azide-alkyne cycloaddition towards 6: Olliaro PL, Merle C, Mthiyane T, Bah B, Kassa F, Amukoye E, N Diaye A, 7: Marcianes P, Negro S, García-García L, Montejo C, Barcia E, 8: Sanfilippo CM, Allaire CM, DeCory HH. Besifloxacin Ophthalmic Suspension 0.6% 9: Kozai S, Wada T, Ogawara KI, Kida T, Tokushige H, Higaki K. Evaluation of 10: Domingos LC, Moreira MV, Keller KM, Viana FA, Melo MM, Soto-Blanco B. |